Provided by Tiger Trade Technology Pte. Ltd.

GT Biopharma Inc.

6.18
+0.20003.34%
Post-market: 6.06-0.1200-1.94%19:30 EDT
Volume:161.35K
Turnover:1.00M
Market Cap:11.15M
PE:-0.47
High:6.74
Open:6.13
Low:5.50
Close:5.98
52wk High:34.25
52wk Low:4.91
Shares:1.80M
Float Shares:1.70M
Volume Ratio:2.60
T/O Rate:9.49%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-13.2195
EPS(LYR):-156.2099
ROE:-113.52%
ROA:-158.16%
PB:3.13
PE(LYR):-0.04

Loading ...

Feb 08, 2021

[Amend]Public Prospectus

S-1/A [Amend] - General form for registration of securities under the Securities Act of 1933
Feb 08, 2021

Beneficial Ownership Change

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
Feb 05, 2021

Beneficial Ownership Change

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
Feb 02, 2021

Major Issues Report

8-K - Current report
Feb 02, 2021

[Amend]Public Prospectus

S-1/A [Amend] - General form for registration of securities under the Securities Act of 1933
Jan 19, 2021

Major Issues Report

8-K - Current report
Dec 31, 2020

Major Issues Report

8-K - Current report
Dec 28, 2020

Major Issues Report

8-K - Current report
Dec 23, 2020

Major Issues Report

8-K - Current report
Dec 11, 2020

Public Prospectus

S-1 - General form for registration of securities under the Securities Act of 1933
Nov 13, 2020

Quarterly Report

10-Q - Quarterly report [Sections 13 or 15(d)]
Nov 09, 2020

Major Issues Report

8-K - Current report
Nov 04, 2020

Major Issues Report

8-K - Current report
Oct 06, 2020

Major Issues Report

8-K - Current report
Sep 22, 2020

Major Issues Report

8-K - Current report
Aug 18, 2020

[Rev.]Quaterly Report

10-Q/A [Amend] - Quarterly report [Sections 13 or 15(d)]
Aug 14, 2020

Quarterly Report

10-Q - Quarterly report [Sections 13 or 15(d)]
Jul 24, 2020

Correspondence

CORRESP [Cover] - Correspondence
Jul 14, 2020

Public Prospectus

S-1 - General form for registration of securities under the Securities Act of 1933
Jul 09, 2020

Major Issues Report

8-K - Current report